Ownership history in B Group, Inc. · 5 quarters on record
This page tracks every 13F SEC filing in which B Group, Inc. reported a position in ULTRAGENYX PHARMACEUTICAL IN (RARE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | UNCHANGED | 135,000 | — | 0% | 2.29% | $3.1M | $23.00 |
| 2025 Q3 | ADDED | 135,000 | +25,000 | +22.7% | 2.99% | $4.1M | $30.08 |
| 2025 Q2 | ADDED | 110,000 | +62,500 | +131.6% | 3.08% | $4.0M | $36.36 |
| 2025 Q1 | ADDED | 47,500 | +39,904 | +525.3% | 1.47% | $1.7M | $36.21 |
As of 2025 Q4 — sorted by position size